Us Bancorp \De\ Dynavax Technologies Corp Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Us Bancorp \De\ holds 2,732 shares of DVAX stock, worth $35,078. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,732

Previous 698 291.4%

Holding current value

$35,078

Previous $7,000 328.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$10.05 - $11.61 $20,441 - $23,614	2,034 Added 291.4%	2,732 $30,000
Q2 2024 Aug 06, 2024	SELL	$10.73 - $12.58 $3,090 - $3,623	-288 Reduced 29.21%	698 $7,000
Q1 2024 May 07, 2024	BUY	$11.7 - $14.98 $1,684 - $2,157	144 Added 17.1%	986 $12,000
Q3 2023 Nov 03, 2023	SELL	$12.64 - $14.99 $1,213 - $1,439	-96 Reduced 10.23%	842 $12,000
Q2 2023 Aug 09, 2023	SELL	$9.85 - $13.17 $20,488 - $27,393	-2,080 Reduced 68.92%	938 $12,000
Q1 2023 May 09, 2023	SELL	$9.44 - $11.88 $2,237 - $2,815	-237 Reduced 7.28%	3,018 $29,000
Q4 2022 Feb 13, 2023	BUY	$10.27 - $13.29 $19,584 - $25,344	1,907 Added 141.47%	3,255 $34,000
Q3 2022 Oct 27, 2022	SELL	$9.93 - $17.44 $4,617 - $8,109	-465 Reduced 25.65%	1,348 $14,000
Q4 2021 Feb 11, 2022	SELL	$13.17 - $20.94 $3,226 - $5,130	-245 Reduced 11.9%	1,813 $26,000
Q2 2021 Aug 05, 2021	SELL	$7.25 - $10.99 $2,312 - $3,505	-319 Reduced 13.42%	2,058 $20,000
Q1 2021 Apr 28, 2021	BUY	$4.57 - $11.18 $1,457 - $3,566	319 Added 15.5%	2,377 $24,000
Q4 2020 Feb 04, 2021	BUY	$3.73 - $5.6 $5,076 - $7,621	1,361 Added 195.27%	2,058 $9,000
Q2 2020 Aug 07, 2020	BUY	$2.94 - $9.1 $2,049 - $6,342	697 New	697 $6,000

Others Institutions Holding DVAX

# of Institutions

275

Shares Held

130M

Call Options Held

451K

Put Options Held

203K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.62B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account